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Antidepressants differentially related to 1,25-(OH)2 vitamin D3
and 25-(OH) vitamin D3 in late-life depression
RC Oude Voshaar1, WJ Derks2, HC Comijs3, RA Schoevers1, MH de Borst4 and RM Marijnissen1,2
A low plasma 25-OH vitamin D3 level is a universal risk factor for a wide range of diseases and has also been implicated in late-life
depression. It is currently unknown whether the biologically active form of vitamin D, that is, 1,25-(OH)2 vitamin D3, is also
decreased in late-life depression, or whether vitamin D levels correlate with speciﬁc depression characteristics. We determined
plasma 25-OH vitamin D3, 1,25-(OH)2 vitamin D3 and parathormone levels in 355 depressed older persons and 124 non-depressed
comparison subjects (age⩾ 60 years). Psychopathology was established with the Composite International Diagnostic Interview 2.1,
together with potential confounders and depression characteristics (severity, symptom proﬁle, age of onset, recurrence, chronicity
and antidepressant drug use). Adjusted for confounders, depressed patients had signiﬁcantly lower levels of 25-OH vitamin D33
(Cohen’s d = 0.28 (95% conﬁdence interval: 0.07–0.49), P= 0.033) as well as 1,25-(OH)2 vitamin D3 (Cohen’s d = 0.48 (95%
conﬁdence interval: 0.27–0.70), Po0.001) than comparison subjects. Of all depression characteristics tested, only the use of tricyclic
antidepressants (TCAs) was signiﬁcantly correlated with lower 1,25-(OH)2 vitamin D3 levels (Cohen’s d = 0.86 (95% conﬁdence
interval: 0.53–1.19), Po0.001), but not its often measured precursor 25-OH vitamin D3. As vitamin D levels were signiﬁcantly lower
after adjustment for confounders, vitamin D might have an aetiological role in late-life depression. Differences between depressed
and non-depressed subjects were largest for the biologically active form of vitamin D. The differential impact of TCAs on 25-OH
vitamin D3 and 1,25-(OH)2 vitamin D3 levels suggests modulation of 1-α-hydroxylase and/or 24-hydroxylase, which may in turn have
clinical implications for biological ageing mechanisms in late-life depression.
Translational Psychiatry (2014) 4, e383; doi:10.1038/tp.2014.14; published online 15 April 2014
INTRODUCTION
Depressive disorders commonly occur in older adults, with
prevalence rates ranging between 1.8 and 9.3%.1,2 The prospec-
tive association between depression and the development and
prognosis of somatic diseases as well as mortality has led to the
postulation of a causal role of ageing-related mechanisms in late-
life depression.3,4 In this respect, 25-(OH) vitamin D3 (or calcidiol) is
of considerable interest. Vitamin D insufﬁciency, deﬁned as a 25-
(OH) vitamin D3 level less than 50 nmol l
− 1, is a universal risk
factor for a range of multifactorial disorders, particularly those
related to aging5,6 like chronic kidney disease, cardiovascular
disease, diabetes, frailty, autoimmune conditions, multiple sclero-
sis and even all-cause mortality.7–10
Recently, 25-(OH) vitamin D3 insufﬁciency has also been
implicated in the pathogenesis of late-life depression.11,12 This
hypothesis, however, is primarily based on cross-sectional studies
showing decreased 25-(OH) vitamin D3 levels in depressed older
persons.11,13,14 Calcitriol (1,25-(OH)2vitamin D3) is the biologically
active form of vitamin D and acts as a neurosteroid on the vitamin
D receptors within the mood regulation brain circuitries.15 1,25-
(OH)2 Vitamin D3 activates gene expression of tyrosine hydro-
xylase, the enzyme responsible for catalysing the conversion of
L-tyrosine to L-DOPA, the precursor of dopamine.15,16 Animal
models of depression clearly point towards a role for the
dopamine system in depression17,18 as well as to a regulatory
role on dopamine-related neurotrophic growth factors for
1,25-(OH)2 vitamin D3. In humans, disturbed dopamine transmis-
sion correlates with the symptoms of apathy and anhedonia in
depression.19 Finally, 1,25-(OH)2 vitamin D3 protects the brain from
neurotoxicity by enhancing gluthathion function.15,20
Although an aetiological role of 25-(OH) vitamin D3 has been
postulated in late-life depression, results showing lowered 25-(OH)
vitamin D3 levels in depression may easily be confounded by
decreased sunlight exposure owing to less outdoor activities,
different clothing habits and season of measurement, malnutri-
tion, low socioeconomic status, dark skin and comorbid somatic
diseases.21–23 A recent meta-analyses identiﬁed an inverse
association between depression and serum vitamin D levels.24
Subgroup analyses by age, however, showed that the inverse
association was only signiﬁcant in persons younger than 60 years
and not in those aged 60 years and over. Negative results could be
explained in one study by correction for self-reported health
status,13 whereas in another study the association between
vitamin D and depressive symptoms was primarily conﬁned to
persons with a history of depression.12 Moreover, one of the ﬁrst
studies on vitamin D levels in (late-life) depression was not
included in the meta-analyses despite meeting the (somewhat
vaguely described) inclusion criteria.11 This cohort study was well
controlled for confounders and found a signiﬁcant inverse
association between serum vitamin D levels and depression.11
Also, not included by having measured vitamin D intake by food
instead of serum levels, was the Women’s Health Initiative
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observational study, in which lower vitamin D intake appeared to
be associated with depressive symptoms.25 Finally, studies
published after conclusion of the search for the meta-analyses
showed that lower vitamin D levels were associated with
depression among 1618 older primary care patients,26 whereas a
small nested case–control study of the Survey in Europe on
Nutrition and the Elder, a Concerted Action study27 as well as a
nursing home study did not.28 Except for the study that took a
history of depression into account,12 characteristics of depression
like age of onset or speciﬁc symptom proﬁles have not been
evaluated systematically in relation to 25-(OH) vitamin D3 levels.
Moreover, no study has evaluated the biologically active form of
vitamin D, that is, 1,25-(OH)2 vitamin D3, in depression.
The objectives of the present study are therefore twofold. First,
to compare vitamin D, both 25-(OH) vitamin D3 and 1,25-(OH)2
vitamin D3 levels, between depressed and non-depressed older
persons. The second objective is to examine the association of
vitamin D levels with speciﬁc depression characteristics (severity,
symptom proﬁle of depressive symptoms, comorbid anxiety
disorders, age of onset, recurrence, chronicity and antidepressant
drug use).
MATERIALS AND METHODS
Sample
For the present study, we used the baseline assessment of the Netherlands
Study of Depression in Older people.29 The Netherlands Study of
Depression in Older people is an on-going cohort study designed to
examine the (determinants of the) course and consequences of depressive
disorders in older 378 depressed and 132 non-depressed persons aged 60
through 93 years. Recruitment of depressed older persons took place in
ﬁve regions in the Netherlands from both mental health care institutes and
general practitioners in order to include persons with late-life depression in
various developmental and severity stages. Persons with a primary
diagnosis of dementia, a Mini Mental State Examination Score under 18
(out of 30 points), and insufﬁcient command of the Dutch language were
excluded. Non-depressed controls were recruited from general practi-
tioners. Inclusion criteria for non-depressed controls were the following: no
lifetime diagnosis of depression, dementia or other serious psychiatric
disorders, and good command of the Dutch language.
Data collection of the baseline assessment started in 2007 and was
ﬁnished in September 2010. The baseline assessment included written
questionnaires, interviews and physical assessments. Interviews were audio
taped to control the quality of the data. The ethical review boards of the
participating institutes have approved this study. All participants gave
informed consent after oral and written information about the study.
For the present study, we excluded 14 persons owing to the missing of a
vitamin D blood sample (no blood withdrawal, n=12; vitamin D
assessment failed, n=2) and 17 because they used vitamin D supple-
mentation. Vitamin D supplementation included vitamin A with vitamin D,
vitamin D and analogue compounds, ergocalciferol, alfacalcidol, calcitriol,
colecalciferol and calcium with colecalciferol.
This resulted in a ﬁnal study sample of 355 depressed older patients and
124 non-depressed controls. Excluded subjects did not differ from
included subjects with respect to age, sex, cognitive functioning (Mini
Mental State Examination Score) or depression status (all P-values>0.36).
Depression diagnoses
The past 6-month diagnosis of depression and dysthymia according to
Diagnostic and Statistical Manual of Mental Disorders-IV-R criteria30 were
assessed with the Composite International Diagnostic Interview (WHO
version 2.1; 12-month version). The Composite International Diagnostic
Interview is a structured clinical interview that is designed for use in
research settings and has high validity for depressive and anxiety
disorders. As in the Netherlands Study of Depression in Adults,31 we
added questions to determine the research Diagnostic and Statistical
Manual of Mental Disorders-IV diagnosis of current minor depression.29
Depression characteristics
Among the depressed sample, 339 (95.5%) met criteria for a major
depressive disorder with the past 6 months, 17 (3.8%) for a minor
depression and 93 (26.2%) for dysthymia. Owing to double diagnoses,
numbers do not add up to 100%. Within the group suffering from a past
6-month major depressive disorder diagnosis, 78 persons did not meet the
criteria for a major depressive disorder within the past month and were
classiﬁed as ‘recently remitted’.
Based on data from the Composite International Diagnostic Interview,
we assessed the age of onset of the depression (age of the participant at
the time of the ﬁrst depressive episode) and recurrence (presence of
depressive episode before the current episode). Severity of depression was
measured by the 30-item self-rating Inventory of Depressive Symptoma-
tology, which has adequate psychometric properties.32 To examine
symptom proﬁles of late-life depression, three subscales of the Inventory
of Depressive Symptomatology were used: a mood, a motivation and a
somatic subscale.33 These three homogenous subscales yielded a good ﬁt
with exploratory and conﬁrmatory factor analysis in the Netherlands Study
of Depression in Older people study.33 Comorbid anxiety was also taken
into account. The Composite International Diagnostic Interview anxiety
diagnosis was used to determine the presence of an anxiety disorder in the
past year that is, generalised anxiety disorders, panic disorder, agoraphobia
or social phobia. The Beck Anxiety Inventory was used to assess the
severity of anxiety symptoms.34 The score on the Beck Anxiety Inventory
was used as a continuous variable. Neuroticism was assessed using the
subscale of the NEO-Five-Factor Inventory.35 Medication use was assessed
on drug container inspection of all drugs used in the past month and
classiﬁed according to the World Health Organization Anatomical
Therapeutic Chemical classiﬁcation.36 Medication was only considered
when taken on a regular basis (at least 50% of the time). Antidepressant
medication was classiﬁed in selective serotonin reuptake inhibitors
(N06AB), tricyclic antidepressants (TCAs; N06AA) and other antidepressants
(N06AX16, N06AX21, N06AX03, N06AX05 and N06AX11).
Vitamin D status
Plasma 25-(OH) vitamin D3 levels were determined using isotope dilution-
online solid-phase extraction liquid chromatography–tandem mass
spectrometry, as described previously.37,38 Method characteristics are the
following: limit of quantitation 4.0 nmol l− 1; intra-assay coefﬁcient of
variationo7.2% and inter-assay coefﬁcient of variationo14.1% for three
concentrations between 20 and 150 nmol l− 1; recovery ranges from 93 to
98% and linearity was acceptable (r2 = 0.9972). The accuracy of 25-(OH)
vitamin D3 levels was established using (the National Institute of Standards
& Technology, Gaithersburg, MD, USA) reference material to establish true
values for calibration standards. Calibration standards, quality control
samples and patient samples were stable for 6 days at 6 °C (coefﬁcient of
variationo11%). Samples were stable for at least three freeze-thaw cycles
(coefﬁcient of variationo3%). The plasma 1,25-(OH)2 D3 was measured by
radioimmunoassay. Standard laboratory measurements were performed as
described previously.39 Subsequently, 25-(OH) vitamin D3 levels were
classiﬁed in categories, that is, severe deﬁcient (o10 nmol l− 1), deﬁcient
(10–24 nmol l− 1), insufﬁcient (25–49 nmol l− 1), hypovitaminosis (50–79)
and optimal (⩾80 nmol l− 1) plasma levels.39,40
The plasma parathyroid hormone concentration was determined by
using a tube sandwich chemiluminescence assay technic (Independent
Lubricant Manufacturers Association) at VU Medical Center Amsterdam, a
highly sensitive method. As summarised in a review on vitamin D,
parathyroid hormone levels are inversely associated with 25-(OH) vitamin
D3 levels until the latter reach 75–100 nmol l
− 1, at which point parathyroid
hormone levels begin to level off (at their nadir).22
Covariates
In addition to demographic variables (age, sex, partner status, years of
education) and astronomical season of blood withdrawal (deﬁned as
winter (21 November-20 February), spring (21 February-20 May), summer
(21 May-20 August), autumn (21 August-20 November)), the following
confounders were a priori considered based on their relationship with
depressive symptoms and vitamin D level.11–13
The ﬁrst set of potential confounders were lifestyle factors and included
smoking, use of alcohol and physical activity. Smoking was deﬁned as
currently smoking (yes/no). On the basis of ﬁrst two questions of the
Alcohol Use Disorder Identiﬁcation Test,41 we classiﬁed alcohol consump-
tion into three categories, that is, no drinking, moderate alcohol use and
problematic alcohol use. Problematic alcohol use was deﬁned as taking
5–10 units on a typical drinking day irrespective of the frequency of
drinking or 3 or 4 units on a typical drinking day at least 4 or more days a
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week. Moderate alcohol use was deﬁned as any alcohol use not being
problematic use. Physical activity in the past week was measured with the
short form (eight items) of the International Physical Activities
Questionnaire.42 Psychometric properties of the long and short version
of the International Physical Activities Questionnaire were acceptable.
The second set of confounders consisted of parameters of physical and
cognitive functioning and included parathyroid hormone (pmol l− 1), renal
function (estimated glomerular ﬁltration rate estimated by the MDRD
(Modiﬁcation of Diet in Renal Disease Study) formula in ml min− 1), waist
circumference (cm) and number of chronic diseases. The number of
chronic diseases was assessed with previously used self-report questions
about the presence of the following chronic diseases or disease events:
cardiac disease (including myocardial infarction), peripheral atherosclero-
sis, stroke, diabetes mellitus, chronic obstructive pulmonary disease
(asthma, chronic bronchitis or pulmonary emphysema), arthritis (rheuma-
toid arthritis or osteoarthritis) and cancer. The accuracy of self-reports of
these diseases was shown to be adequate and independent of cognitive
impairment compared with data obtained from general practitioners.43
Global cognitive functioning was measured by the Mini Mental State
Examination.44 The Mini Mental State Examination Score ranges from 0 to
30, with higher scores indicating better cognitive functioning.
Statistical analysis
In order to obtain a normal distribution of plasma 1,25-(OH)2vitamin D3
and parathormone (PTH) levels, respectively, two positive outliers were
trimmed at the mean level plus 3 s.d., resulting in a skewness of 0.76 (s.
e. = 0.11) and kurtosis of 1.35 (s.e. = 0.22) for 1,25-(OH)2 vitamin D3 and
skewness of 2.02 (s.e. = 0.13) and kurtosis of 7.31 (s.e. = 0.26) for PTH. The
latter was log transformed in order to get a normal distribution. All other
continuous variables had a normal distribution.
Potential determinants of 25-(OH) vitamin D3, 1,25-(OH)2 vitamin D3 and
PTH levels were ﬁrst compared between depressed and non-depressed
persons with Student’s t-tests for continuous variables and Pearson’s
χ2-tests for categorical variables. Thereafter, these potential determinants
were entered as covariates in the analysis of covariance with plasma
25-(OH) vitamin D3, 1,25-(OH)2 vitamin D3 and PTH levels as dependent
variables. Cohen’s d, deﬁned as the difference between two means divided
by the pooled s.d. of the two means, was used to evaluate the effect size. A
Cohen’s d of >0.2 is considered a small effect, >0.5 a medium effect and
>0.8 a large effect.45
Finally, we examined the relationship between several characteristics of
depressive disorder as independent variables in multiple linear regression
analyses with 25-(OH) vitamin D3 and 1,25-(OH)2vitamin D3 levels as the
dependent variables within the depressed subgroup, adjusted for all
covariates described above.
All analyses were carried out using the Statistical Package for the Social
Sciences (SPSS) version 20.0 (IBM SPSS, Armonk, NY, USA).
RESULTS
The 355 depressed older patients (34.1% male) had a mean (s.d.)
age of 70.7 (7.4) years; the 124 non-depressed persons (35.5%
male) had a mean (s.d.) age of 69.9 (7.3) years. Table 1 presents the
other characteristics of the study population by depression status.
As shown, depressed and non-depressed groups signiﬁcantly
differed with respect to educational level, use of alcohol, smoking,
physical activity, waist circumference, renal function, number of
chronic diseases and cognitive functioning.
The distribution of the 25-(OH) vitamin D3 levels over the ﬁve
predeﬁned categories showed that among depressed older
persons no one had a severe deﬁciency (o10 nmol l− 1 or 4.0
ngml− 1), 36 (10.1%) a deﬁciency (10–24 nmol l− 1 or 4.0–10.0 ng-
ml− 1), 149 (42.0%) insufﬁciency (25–49 nmol l− 1 or 10.0–20.0 ng-
ml− 1), 127 (35.8%) hypovitaminosis D (50–79 nmol l− 1 or
20.0–32.0 ngml− 1) and 43 (12.1%) had optimal levels (⩾80
nmol l− 1 or 32.0 ngml− 1). Cross tabulation showed that the
distribution of the ﬁve categories was signiﬁcantly different
between the depressed group versus the control group
(χ2 = 16.3, df = 3, P= 0.001) with a higher frequency of the lower
categories in the depressed group.
As shown in Table 2, mean (s.d.) levels of 25-(OH) vitamin D3 as
well as 1,25-(OH)2 vitamin D3 differed signiﬁcantly between
depressed and non-depressed older persons, whereas PTH levels
did not. After adjustment for potential confounders (see notes in
Table 1. Baseline characteristics of study sample by depression status (n= 479)
Characteristic Depressed patients (n= 355) Non-depressed controls (n=124) Statistics
Sociodemographics
Age, mean (s.d.) 70.7 (7.4) 69.9 (7.2) t=− 0.967, df= 477, P= 0.334
Male sex, n (%) 121 (34.1) 49 (39.5) Χ2= 1.18, df= 1, P= 0.276
Educational level (years), mean (s.d.) 10.5 (3.4) 12.4 (3.5) t= 5.44, df= 477, P= 0.000
Seasons of measurement
Spring, n (%) 113 (31.8) 41(33.1) Χ2= 7.09, df= 3, P= 0.069
Summer, n (%) 94 (26.5) 46 (37.1)
Autumn, n (%) 74 (20.8) 17 (13.7)
Winter, n (%) 74 (20.8) 20 (16.1)
Lifestyle
Use of alcohol
No alcohol use, n (%) 140 (40.0) 17 (14.2) Χ2= 31.21, df= 2, P= 0.000
Moderate alcohol use, n (%) 178 (50.9) 78 (65.0)
Severe alcohol use, n (%) 32 (9.1) 25 (20.8)
Smoking (yes), n (%) 91 (25.9) 10 (8.1) Χ2= 17.36, df= 1, P= 0.000
Physical activity
Low, n (%) 107 (31.1) 22 (18.3) Χ2= 7.5, df= 2, P= 0.024
Moderate, n (%) 130 (37,8) 51 (42,5)
High, n (%) 107 (31.1) 47 (39,2)
Waist circumference (cm), mean (s.d.) 93.51 (12.81) 98.99 (15.26) t= 3.88, df= 474, P= 0.000
Physical functioning
No. of chronic diseases, mean (s.d.) 2.09 (1.44) 1.47 (1.11) t=− 4.39, df= 476, P= 0.000
Cognitive functioning (MMSE), mean (s.d.) 27.69 (2.00) 28.32 (1.58) t= 3.08, df= 476, P= 0.002
Renal function (eGFR, ml min− 1), mean (s.d.) 75.1 (18.04) 78.8 (16.67) t= 1.99, df= 477, P= 0.048
Abbreviations: eGFR, estimated glomerulate ﬁltration rate; MMSE, Mini Mental State Examination.
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Table 2), the differences in vitamin D levels remained signiﬁcant
(see Table 2 and Figure 1). Moreover, results did not change
substantially after additional correction for PTH levels: the
estimated marginal means (s.e.) for depressed and non-
depressed persons were 53.0 (1.2) and 58.2 (2.1) nmol l− 1 for
25-OH vitamin D3 (F = 4.2; df = 1,433; P= 0.040) and 137.9 (2.4) and
160.0 (4.4) pmol l− 1 for 1,25-(OH)2 vitamin D3 (F = 17.6; df = 1,433;
P= 0.039), respectively.
Subsequently, we checked whether we could identify char-
acteristics of depression that were speciﬁcally associated with
vitamin D levels within the depressed group. As shown in Table 3,
none of the characteristics correlate with the 25-(OH) vitamin D3
levels. Only the use of antidepressants was signiﬁcantly correlated
with the level of 1,25-(OH)2 vitamin D3.
Of the 257/355 (72.4%) patients using antidepressants, 99
patients used a selective serotonin reuptake inhibitor, 75 patients
a TCA and 100 patients another antidepressant (numbers do not
add to 257 as 17 patients used antidepressants from more than
one class). Further exploration of the association between
antidepressant drug use and lower levels of 1,25-(OH)2 vitamin
D3 showed that the impact of antidepressant drug use was driven
by TCAs (see Table 4). As these ﬁndings may be confounded by
indication, we additionally adjusted the analyses for the severity of
depressive symptoms as well as for inversus outpatient status.
These additional adjustments did not change the results.
Figure 2 presents the estimated marginal means adjusted for
confounders for depressed persons not using any antidepressants
and those using SSRIs, TCAs or other antidepressants (after having
excluded 17 persons who used two or more types of
antidepressants).
DISCUSSION
Main ﬁndings
Adjusted for potential confounders, depressed older persons had
signiﬁcantly lower 25-OH vitamin D3 and 1,25-(OH)2 vitamin D3
compared with their non-depressed counterparts, with a small
and medium effect size, respectively. Of the 355 depressed older
patients, only 12.1% had optimal (>80 nmol l− 1 or 32 ngml− 1) 25-
OH vitamin D3 levels, whereas 52.1% had insufﬁcient (o50 nmol
l− 1 or 20 ngml− 1) levels and even more than 10% a deﬁciency
(o25 nmol l− 1 or 10 ngml− 1). None of the characteristics of
depression was associated with 25-(OH) vitamin D3 levels, whereas
the use of antidepressants was signiﬁcantly associated with lower
1,25-(OH)2 vitamin D3 levels only. In particular, persons using
tricylic antidepressants (TCA) had lower 1,25-(OH)2 vitamin D3
levels, which could neither be explained by depression severity
nor by an inpatient setting.
Comparison with previous ﬁndings
To our knowledge, this is the ﬁrst study comparing the biologically
active vitamin D form between depressed and non-depressed
persons in a sufﬁciently large sample and adequate confounder
control. One older pilot study also found lower vitamin D levels,
including 1,25-(OH)2 vitamin D3 levels, in 25 depressed compared
with 31 non-depressed middle-aged persons.46 Interpretation of
that study is hampered, because only unadjusted results are
presented and no information is given on the assays used.
Interestingly, the differences between depressed and non-
depressed persons were largest for the biologically active form
of vitamin D, suggesting that the usually measured inactive form
may underestimate the hypothesised pathophysiological role of
vitamin D in late-life depression.
Table 2. Unadjusted and adjusted mean (s.e.) vitamin D and PTH levels by depression status
Variable Depressed patients (n=355) Non-depressed controls (n= 124) Statistics Cohen’s d (95% CI)
Unadjusted analyses
25-OH-vitamin D3 (nmol l
− 1) 51.9 (1.2) 62.0 (2.1) F= 17.66, df= 1, Po0.001 0.45 (0.24–0.67)
1,25-diOH-vitamin D3 (pmol l
− 1) 136.7 (2.5) 163.7 (3.9) F= 31.27, df= 1, Po0.001 0.61 (0.39–0.83)
Parathormone (PTH) (pmol l− 1)a 0.82 (0.19) 0.80 (0.19) F= 1.55, df= 1, P= 0.213 Not relevant
Adjusted for covariatesb
25-OH vitamin D3 (nmol l
− 1) 52.9 (1.2) 58.3 (2.1) F= 4.59, df= 1, P= 0.033 0.28 (0.07–0.49)
1,25-(OH)2 vitamin D3 (pmol l
− 1) 138.0 (2.5) 159.6 (4.4) F= 16.93, df= 1, Po0.001 0.48 (0.27–0.70)
Parathormone (PTH) (pmol l− 1)a 0.82 (0.10) 0.81 (0.18) F= 0.181, df= 1, P= 0.670 Not relevant
Abbreviation: CI, conﬁdence interval. aAnalyses based on log-transformed values. bAdjusted for age, sex, educational level, season of measurement, use of
alcohol, smoking, physical activity, waist circumference, number of chronic diseases, cognitive functioning and renal function (see Table 1 for units and/or
categories of the covariates).
Figure 1. (a–c) Adjusted marginal mean values (with error bars representing the s.e.m.) of 25-(OH) vitamin D3, 1,25‐(OH)2 vitamin D3 and
parathormone (PTH) levels in depressed versus non-depressed persons.
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Our ﬁndings of lowered levels of 25-OH vitamin D3 levels in
depression extends previous population-based studies showing
reduced levels of 25-OH vitamin D3 levels in community-dwelling
older persons with depressive symptoms or disorders,11–13,47 and
are in line with much smaller controlled46 and uncontrolled48
hospital-based studies.
In line with most previous studies on the association between
depression and vitamin D, we did not ﬁnd any association
between increased PTH levels and depression.49,50 Nonetheless,
some studies did ﬁnd this association.11 The lack of a consistent
association between depression and PTH level may point to
speciﬁc effects for vitamin D in depression, but may also be simply
explained by PTH being a less sensitive marker for depression
compared with vitamin D, as PTH is essential for minute-to-minute
regulation serum-ionised calcium, whereas vitamin D effects are
more delayed.50,51
So far, three prospective studies are available, which found a
two times higher risk to develop a depression when 25-OH
vitamin D3 levels are below 50 nmol l
− 1 (refs. 52–54) and even
tripled risk when levels are smaller than 15 nmol l− 1.52 None-
theless, results of intervention studies using vitamin D3
supplementation are inconsistent. Positive effects on the improve-
ment of depressive symptoms have been reported for vitamin D3
supplements55 and for vitamin D3 as adjunct to ﬂuoxetine,
56
whereas others did not ﬁnd any effect.57–60
Impact of antidepressant drug use
None of the tested depression characteristics were associated with
25-OH vitamin D3 levels, whereas TCA usage was associated with
lower levels of 1,25-(OH)2 vitamin D3 in depressed persons. This
association seems puzzling at ﬁrst glance. Post hoc analyses with
additional adjustment for depression severity and an inpatient
setting in order to attempt to control for confounding by
indication did not explain the association.61,62 Our results there-
fore may point to a true effect of TCAs on 1,25-(OH)2 vitamin D3
levels. Hydroxylation of 25-OH vitamin D3 to the biologically active
compound 1,25-(OH)2 vitamin D3 is catalysed by 1-α-hydroxylase
(CYP27B1). 1-α-Hydroxylase is strongly expressed in the kidney
and strictly regulated by calcium, PTH and phosphate levels.
Interestingly, 1 α-hydroxylase is also expressed in the brain tissue,
but in contrast to the kidney, not regulated by calcium-related
Table 3. Association between vitamin D levels and speciﬁc characteristics of depression by separate linear regression adjusted for confoundersa
within the depressed group
Characteristic Mean (s.d.) Calcidiol (25-(OH)D3) Calcitriol (1,25-(OH)2D3)
or n (%) B (s.e.) β P B (s.e.) β P
Depression severity (IDS) 30.1 (13.0) − 0.14 (0.10) − 0.077 0.174 − 0.10 (0.21) − 0.026 0.631
IDS mood subscale 9.0 (5.2) − 0.15 (0.25) − 0.034 0.540 − 0.10 (0.51) − 0.011 0.837
IDS motivation subscale 5.0 (3.1) − 0.25 (0.41) − 0.034 0.537 − 0.22 (0.83) − 0.014 0.789
IDS somatic subscale 9.7 (4.2) − 0.40 (0.30) − 0.071 0.204 0.03 (0.63) 0.003 0.962
Age of onset, continuous (years) 48.6 (20.4) 0.04 (0.06) 0.032 0.556 0.14 (0.13) 0.058 0.280
Late onset depression (>60 years) 117 (33.5) − 2.07 (2.63) − 0.043 0.432 − 2.77 (5.46) − 0.027 0.612
Recurrent depression 162 (45.6) 2.02 (2.49) 0.044 0.417 3.51 (4.97) 0.037 0.480
Recently remitted depression 94 (26.5) − 3.50 (2.87) − 0.064 0.224 − 2.66 (5.42) − 0.03 0.625
Double diagnosesb (y/n) 93 (26.2) 0.04 (0.06) 0.032 0.556 − 6.79 (5.44) − 0.063 0.213
Use of antidepressants (y/n) 257 (72.4) − 3.40 (2.63) − 0.067 0.197 − 13.72 (5.31) − 0.130 0.010
Comorbid anxiety disorder (any) 140 (39.4) − 1.43 (2.49) − 0.031 0.567 3.55 (5.06) 0.036 0.484
Anxiety severity (BAI) 17.4 (11.3) − 0.08 (0.11) − 0.040 0.472 0.15 (0.23) 0.037 0.496
Neuroticism 39.0 (7.1) − 0.03 (0.18) − 0.009 0.867 − 0.14 (0.35) − 0.021 0.695
Abbreviations: BAI, Beck Anxiety Inventory; IDS, Inventory of Depressive Symptoms; MDD, major depressive disorder; y/n, yes/no. aAdjusted for age, sex,
educational level, season of measurement, use of alcohol, smoking, physical activity, waist circumference, number of chronic diseases, cognitive functioning
and renal function (see Table 1 for units and/or categories of the covariates). bMDD and dysthymia.
Table 4. Association between vitamin D levels, severity of depressive symptoms and use of antidepressants in one, fully adjusted linear regression
model (n= 355)
Characteristic Calcidiol (25-(OH)D3) Calcitriol (1,25-(OH)2D3)
B (s.e.) β P B (s.e.) β P
Model 1 (n=355)
Use of a SSRI (1= yes) − 1.73 (2.93) − 0.03 0.553 − 7.84 (5.78) − 0.07 0.176
Use of a TCA (1= yes) − 3.65 (3.37) − 0.07 0.280 − 31.78 (6.64) − 0.27 o0.001
Use of other antidepressants (1= yes) − 3.84 (2.89) − 0.08 0.184 − 2.23 (5.69) − 0.02 0.695
Model 2 (n=355)
Use of a SSRI (1= yes) − 1.01 (2.95) − 0.02 0.732 − 7.03 (5.82) − 0.07 0.228
Use of a TCA (1= yes) − 2.08 (3.49) − 0.04 0.553 − 28.13 (6.89) − 0.24 o0.001
Use of other antidepressants (1= yes) − 3.69 (2.88) − 0.07 0.201 − 1.79 (5.68) −0.02 0.753
Abbreviations: eGFR, estimated glomerular ﬁltration rate; MMSE, Mini Mental State Examination; SSRI, selective serotonin reuptake inhibitor; TCA, tricyclic
antidepressants. Model 1: Adjusted for age, sex, level of education, smoking status (yes/no), alcohol use (no, moderate, severe), physical activity (low, medium,
large), waist circumference, renal function (eGFR), chronic comorbid diseases and global cognitive functioning (MMSE). Model 2: Similar to model 1, but
additionally adjusted for depressive symptom severity and inversus outpatient status.
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pathways. Moreover, 1,25-(OH)2 vitamin D3 can be inactivated by
1,25-(OH)2 vitamin D3 24-hydroxylase (CYP24A1), which is also
present in the brain. Vitamin D3 signalling may thus involve
autocrine and paracrine pathways in the brain, as the biologically
active form can be synthesised and eliminated. We hypothesise
that TCAs may dampen 1-α-hydroxylase activity and induce the
activity of 1,25-(OH)2 vitamin D3 24-hydroxylase.
For a detailed overview of vitamin D physiology in the brain, we
refer to a recent review by Eyles et al.15 In brief, vitamin D has a
neuroprotective role in the brain by reducing harmful cellular
processes by functioning like an immunosuppressor, stimulating
neurogenesis and clearance of amyloid beta and regulating the
synthesis of neurotrophic factors, important for cell differentiation
and survival.63,64 It has been hypothesised that the regulatory
effect of 25-OH and 1,25-(OH)2vitamin D3 on the vitamin D
receptor in the degenerating brain might fail and induce ageing
mechanisms, like genomic instability, neuroendocrine dysfunction,
production of oxidative compounds, altered calcium metabolism
and inﬂammatory neuron damage.5 Whether TCAs may accelerate
biological ageing mechanisms in depressed older persons through
modulation of 1-α-hydroxylase and/or 24-hydroxylase activity
should be addressed in future studies.
Methodological considerations
Although this study was conducted within a large and well-
phenotyped cohort of depressed and non-depressed older
persons, two limitations deserve attention. First, vitamin D3 levels
were measured peripherally giving no information about the
actual level in the brain. Nonetheless, it is assumed that the free
fraction of 25-(OH) and 1,25-(OH)2 vitamin D3 freely crosses the
blood–brain barrier being small and lipophilic molecules via
energy-independent passive mechanisms.15 Furthermore, the free
fraction of 25-OH vitamin D3 and 1,25-(OH)2 vitamin D3 enters cells
via energy-independent passive mechanisms, but its level of
penetration remains unknown.15 Second, owing to its cross-
sectional design no causal inferences can be made, as residual
confounding can never be fully excluded. Residual confounding
due to ethnicity or skin tone seems unlikely as only 26 participants
(7 controls, 19 patients) were born outside Western Europe, but
residual confounding, for example, because of sunscreen use
cannot be excluded. Similarly, we can deﬁnitely rule out that the
association with TCAs depends on confounding by indication as
depression severity and setting are not the sole indicators for
prescribing TCAs.
Future implications
First, experimental studies should be set up to test the effect of
different classes of antidepressant drugs on vitamin D metabolism.
If proven, the clinical impact of antidepressant drug use on the
contribution to biological ageing mechanism should be explored.
Unravelling these underlying mechanisms may shed more light on
mixed results of randomised controlled trials on the efﬁcacy of
vitamin D supplementation57–60 with respect to the prevention
and treatment of depression.
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